References
- Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83–103.
- Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998–1006.
- Aricò M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28:4755–4761.
- Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol. 2009;27:5175–5181.
- Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children’s oncology group study AALL0031. Leukemia. 2014;28:1467–1471.
- Rives S, Estella J, Gómez P, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish cooperative group SHOP studies ALL-94, ALL-99 and ALL. Br J Haematol. 2011;154:600–2005. 11.
- Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome positive acute lymphoblastic leukemia (EsPhALL): a randomized, open-label, intergroup study. Lancet Oncol. 2012;13:936–945.
- Mostert S, Arora RS, Arreola M, et al. Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group. Lancet Oncol. 2011;12:719–720.
- Luo XQ, Ke ZY, Huang LB, et al. High-risk childhood acute lymphoblastic leukemia in China: factors influencing the treatment and outcome. Pediatr Blood Cancer. 2009;52:191–195.